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Summary
Objective:  The  liver  plays  a  major  role  in  the  metabolism  and  elimination  of  many  antiepilep-
tic drugs  (AEDs),  including  perampanel.  Some  of  the  metabolites  identiﬁed  for  perampanel  are
likely formed  via  reactive  intermediates,  which  have  the  potential  to  covalently  bind  to  protein
and cause  idiosyncratic  toxicities,  including  hepatotoxicity.  The  approved  AED  perampanel  is  a
selective,  noncompetitive  AMPA  receptor  antagonist.  The  safety  and  tolerability  of  perampanel
have been  well  documented  in  3  double-blind,  randomized,  placebo-controlled,  phase  III  stud-
ies. Here  we  report  the  effects  of  perampanel  on  liver  function  in  patients  from  the  phase  III
studies to  assess  the  potential  for  liver  toxicity.
Methods:  Following  6-week  baseline,  patients  (≥12  years  old)  with  drug-resistant  partial
seizures were  randomized  to  once-daily  double-blind  treatment  (6-week  titration,  13-week
maintenance)  with  2,  4,  8,  or  12  mg  perampanel  (n  =  1038)  or  with  placebo  (n  =  442).  Clinical
laboratory  tests  for  hepatobiliary  laboratory  parameters  were  evaluated  at  baseline  and  at
end of  treatment.  These  included  alanine  aminotransferase,  alkaline  phosphatase,  aspartate
aminotransferase,  gamma-glutamyl  transpeptidase,  and  total  bilirubin.  Treatment-emergent
markedly  abnormal  values  (an  increase  in  NCI-CTC  grade  relative  to  baseline  and  a  grade  ≥2)
and treatment-emergent  adverse  events  (TEAEs)  related  to  hepatobiliary  parameters  were  also
recorded.
Abbreviations: AE, adverse event; AED, antiepileptic drug; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-
lutamyl transferase; NCI-CTC, National Cancer Institute Common Toxicity Criteria; TEAE, treatment-emergent adverse event; ULN, upper
imit of normal.
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Introduction
Approximately  2.2  million  Americans  are  currently  diag-
nosed  with  epilepsy,  a  chronic  disease  of  the  brain  in  which
patients  can  have  at  least  2  unprovoked  seizures  occurring
>24  h  apart;  1  unprovoked  seizure  and  a  probability  of  fur-
ther  seizures  similar  to  the  general  recurrence  risk  (≥60%)
after  two  unprovoked  seizures,  occurring  over  the  next  10
years;  or  a  diagnosis  of  an  epilepsy  syndrome  (Fisher  et  al.,
2014;  Institute  of  Medicine  of  the  National  Academies  et  al.,
2012).  Abnormal  excessive  or  synchronous  neuronal  activ-
ity  in  the  brain  results  in  an  epileptic  seizure  (Fisher  et  al.,
2005).  Initial  treatment  of  epilepsy  requires  the  therapeutic
use  of  antiepileptic  drugs  (AEDs)  in  order  to  control  seizures,
avoid  drug-induced  adverse  events,  and  maintain  quality  of
life  (Elger  and  Schmidt,  2008).
Many  drugs,  including  AEDs,  are  metabolized  and  elim-
inated  by  the  liver  (Ahmed  and  Siddiqi,  2006;  Hussein
et  al.,  2013;  Lee,  1995),  and  thus  there  is  the  potential
for  drug-induced  liver  injury/toxicity  (Hussein  et  al.,  2013).
For  some  AEDs,  such  as  valproic  acid  and  felbamate,  a
risk  of  hepatotoxicity  is  evident  and  linked  to  the  forma-
tion  of  reactive  metabolic  intermediates  (Zaccara  et  al.,
2007).  Reactive  intermediates  have  the  potential  of  cova-
lently  binding  to  proteins,  especially  if  reduced  glutathione
(GSH)  levels  become  depleted,  thus  impairing  detoxiﬁca-
tion  (Ballet,  2010;  Begriche  et  al.,  2011;  Evans  et  al.,  2004;
Lammert  et  al.,  2010).  This  mechanism  is  considered  to  play
a  role  in  causing  idiosyncratic  toxicities,  including  hepato-
toxicity  (Ballet,  2010;  Evans  et  al.,  2004;  Lammert  et  al.,
2010).  However,  there  is  also  evidence  of  a  clinical  daily
dose  threshold  below  10  mg/day  for  which  idiosyncratic  tox-
icities  are  rare  (Ballet,  2010;  Evans  et  al.,  2004;  Nakayama
et  al.,  2009;  Uetrecht,  2001).  Additionally,  the  metabolite  of
the  parent  drug  and/or  the  products  of  oxidation  can  cause
injury  to  hepatic  cell  components  as  well  as  the  bile  ducts,
causing  cholestasis  (Lee,  1995).  A  number  of  blood  tests
measuring  liver  enzyme  levels  can  assist  in  determining  the
health  of  the  liver  (Pratt  and  Kaplan,  2000).  Alanine  amino-
transferase  (ALT)  and  aspartate  aminotransferase  (AST)  can
serve  as  markers  of  hepatocellular  injury,  while  alkaline
phosphatase  (ALP)  and  gamma-glutamyl  transferase  (GGT)
can  indicate  an  obstruction  in  the  bile  ducts,  cholestasis,
or  hepatobiliary  disease  (Hussein  et  al.,  2013;  Pratt  and
Kaplan,  2000).  A  few  AEDs  are  associated  with  drug-induced
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s  were  within  normal  ranges  at  baseline  and  end  of  treatment
acebo.  Mean  changes  from  baseline  to  end  of  treatment  were
 abnormal  results  was  very  low  for  perampanel  and  placebo.
rameters  occurred  in  0.4%  of  perampanel  patients  and  0%  of
sorders  included  cholelithiasis  (n  =  3  in  perampanel)  and  abnor-
mpanel).  None  of  the  events  were  serious  or  led  to  perampanel
alues  that  met  the  criteria  for  Hy’s  Law.
ory  data  and  related  TEAEs  were  not  notably  different  between
nt  groups,  and  no  dose-related  trends  were  observed.  Based  on
hase  III  studies,  perampanel  (2,  4,  8,  and  12  mg)  demonstrated
liver  function  tests,  indicating  perampanel  is  an  AED  with  a  low
xicity.
 Elsevier  B.V.  This  is  an  open  access  article  under  the  CC  BY-
mmons.org/licenses/by-nc-nd/4.0/).
iver  toxicity  and  require  regular  monitoring  of  liver  enzymes
r  discontinuation  of  the  drug  (Hussein  et  al.,  2013;  Warner
t  al.,  1998).
Perampanel  is  a  ﬁrst-in-class,  orally  active,  noncom-
etitive,  selective  AMPA  glutamate  receptor  antagonist
pproved  in  more  than  40  countries,  including  the  United
tates  and  in  the  European  Union,  for  adjunctive  treatment
f  partial  seizures  with  or  without  secondarily  general-
zed  seizures,  in  patients  with  epilepsy  aged  ≥12  years  (in
anada,  perampanel  is  approved  in  patients  aged  ≥18  years)
FYCOMPA  SPC,  2012;  FYCOMPA  Product  Monograph,  2013;
YCOMPA  Prescribing  Information,  2014;  Hanada  et  al.,
011;  Krauss  et  al.,  2013).  The  efﬁcacy  and  safety  of
erampanel  in  patients  with  treatment-resistant  partial
eizures  have  been  demonstrated  in  three  multicenter,
ouble-blind  (DB),  randomized,  parallel-group,  placebo-
ontrolled,  phase  III  studies  (French  et  al.,  2012,  2013;
rauss  et  al.,  2012).  Similar  to  other  AEDs  that  are  metab-
lized  predominantly  by  the  liver  (Ahmed  and  Siddiqi,
006),  perampanel  is  extensively  metabolized  via  CYP3A4
nd  CYP3A5  enzymes,  with  the  main  pathway  being  oxida-
ion  and  subsequent  glucuronidation  (Rektor,  2013;  Rogawski
nd  Hanada,  2013).  The  potential  for  perampanel  to  result
n  liver  toxicity  was  intensively  assessed  clinically  using
he  data  from  the  three  Phase  III  studies.  Here  we  report
he  comprehensive  evaluation  of  perampanel  on  liver  func-
ion  tests  undertaken  to  assess  the  potential  for  liver
oxicity.
ethods
he  three  phase  III  studies  (study  304:  NCT00699972;  305:
CT00699582;  306:  NCT00700310)  were  conducted  between
pril  2008  and  January  2011  (French  et  al.,  2012,  2013;
rauss  et  al.,  2012).  All  studies  were  compliant  with
he  Helsinki  Declaration,  the  European  Medicines  Agency
equirements,  and  the  US  Code  of  Federal  Regulations,  as
ppropriate.  Study  protocols,  amendments,  and  informed
onsents  were  reviewed  by  national  regulatory  authorities  in
ach  country  and  by  independent  ethics  committees  or  insti-
utional  review  boards  for  each  site.  All  patients  provided
ritten  informed  consent  before  participation.
The  three  phase  III  core  studies  were  randomized,
ouble-blind,  placebo-controlled  evaluations  of  adjunctive
78  A.  Laurenza  et  al.
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erampanel  at  doses  of  2  mg/day  to  12  mg/day.  Following
 6-week  baseline  period,  patients  were  randomized  to
nce-daily,  double-blind,  19-week  treatment  (6-week  titra-
ion,  13-week  maintenance)  with  placebo  or  perampanel
 or  12  mg  (Studies  304  and  305)  or  with  placebo  or
erampanel  2,  4,  or  8  mg  (Study  306)  (Fig.  1).  Patients
ncluded  in  these  studies  were  aged  ≥12  years  with
rug-resistant  partial  seizures  and  were  receiving  1—3  con-
omitant  AEDs.  The  detailed  inclusion  and  exclusion  criteria
or  all  three  studies  have  been  published  previously  (French
t  al.,  2012,  2013;  Krauss  et  al.,  2012).  During  the  6-
eek  titration  period,  perampanel  doses  were  increased  by
 mg/day/week  until  the  randomized  dose  or  intolerability
as  reached  (French  et  al.,  2012,  2013;  Krauss  et  al.,  2012).
uring  the  13-week  treatment  period,  patients  continued
n  the  dose  achieved  during  titration.  Patients  also  contin-
ed  receiving  their  established  concomitant  AEDs  without
odiﬁcation.
Blood  samples  were  taken  at  screening;  baseline;  weeks
,  10,  14,  19,  and  23;  and  discontinuation.  Clinical
aboratory  tests  for  hepatobiliary  laboratory  parameters
ere  evaluated  at  baseline  and  at  the  end  of  treat-
ent  for  the  following:  alkaline  phosphatase  (ALP);
lanine  aminotransferase  (ALT);  aspartate  aminotransferase
AST);  gamma-glutamyl  transpeptidase  (GGT);  and  total
ilirubin.
Hepatobiliary  laboratory  data  were  summarized  through
escriptive  statistics  and  shift  tables  relative  to  laboratory
ormal  range.  Treatment-emergent  markedly  abnormal  val-
es,  deﬁned  as  laboratory  results  that  worsened  in  severity
elative  to  baseline,  to  meet  modiﬁed  National  Cancer  Insti-
ute  Common  Toxicity  Criteria  (NCI-CTC)  of  ≥grade  2,  were
lso  captured.
Based  on  liver  function  tests,  additional  analyses  were
erformed.  For  ALP,  ALT,  AST,  and  GGT,  the  number  of
atients  with  values  that  were  ≤3×  the  upper  limit  of
ormal  (ULN),  >3×  ULN  but  ≤5×  ULN,  and  >5×  ULN  was  cal-
ulated;  and  for  total  bilirubin,  the  number  of  patients  with
alues  ≤2×  ULN  and  >2×  ULN  was  calculated.  Treatment-
mergent  adverse  events  (TEAEs)  related  to  hepatobiliary
arameters  were  also  recorded.
a
m
v
ndies  304,  305,  and  306.
esults
ean  hepatobiliary  laboratory  values
he  safety  population  of  the  phase  III  pooled  studies
ncluded  1038  patients  treated  with  perampanel  (2  mg,
 =  180;  4  mg,  n  =  172;  8  mg,  n  =  431;  12  mg,  n  = 255)  and  442
atients  treated  with  placebo.  Fig.  2  shows  mean  values  for
epatobiliary  laboratory  parameters  taken  at  baseline  and
t  the  end  of  treatment  in  patients  in  the  placebo  and  per-
mpanel  treatment  groups.  Mean  values  of  ALP,  ALT,  AST,
GT,  and  total  bilirubin  were  within  normal  ranges  at  base-
ine  and  end  of  treatment  for  all  perampanel  dose  groups  and
lacebo.  Mean  changes  from  baseline  to  end  of  treatment
ere  small  and  not  meaningful.
hift  from  baseline  to  end  of  treatment  in
epatobiliary  laboratory  values
hifts  in  values  from  baseline  to  end  of  treatment  for  hepa-
obiliary  laboratory  parameters,  relative  to  normal  ranges,
ere  not  of  clinical  concern  (Table  1).  The  majority  of
epatobiliary  parameters  for  perampanel  and  placebo  were
ormal  at  baseline  and  remained  normal  at  end  of  treat-
ent.  The  percent  of  patients  treated  with  perampanel
hat  had  hepatobiliary  parameters  values  within  the  normal
ange  at  the  end  of  treatment  was  similar  to  placebo-treated
atients  (Table  1).
reatment-emergent  markedly  abnormal
epatobiliary  parameters
s  shown  in  Table  2, treatment-emergent  markedly  abnor-
al  results  (an  increase  in  NCI-CTC  grade  relative  to  baseline
nd  a  grade  ≥2)  occurred  in  ≤3.1%  of  patients  in  any  treat-
ent  group.  The  incidence  of  markedly  abnormal  results  was
ery  low  for  perampanel-  and  placebo-treated  patients,  and
o  dose-related  trends  were  observed.
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rFig.  2  Mean  hepatobiliary  laboratory  parameters  at  baseline  a
within normal  ranges.  ALP  =  alkaline  phosphatase;  ALT  =  alanine  
glutamyl transpeptidase;  PER  =  perampanel.
Laboratory  values  of  special  interest—–Additional
liver  function  tests
Hepatobiliary  laboratory  values  of  special  interest  are  shown
in  Table  3.  For  ALP,  ALT,  and  AST,  there  were  no  patients
from  any  treatment  group  who  had  values  >5×  ULN.  Val-
ues  that  were  >3×  ULN  but  ≤5×  ULN  occurred  in  similarly
low  percentages  in  patients  treated  with  perampanel  (0.5%,
0.3%,  0.1%  for  AST,  ALT,  and  ALP,  respectively)  and  those
treated  with  placebo  (0.2%,  0.2%,  0%  for  AST,  ALT,  and  ALP,
respectively).  There  were  no  dose-related  trends  across
p
p
a
bnd  of  treatment  for  placebo  and  perampanel  (PER)  groups  were
otransferase;  AST  =  aspartate  aminotransferase;  GGT  =  gamma-
he  perampanel  groups.  For  GGT,  values  >5×  ULN  were
bserved  in  1.8%  (n  =  18)  and  2.1%  (n  =  9)  of  all  perampanel-
reated  and  placebo-treated  patients,  respectively.  GGT
alues  that  were  >3×  ULN  but  ≤5×  ULN  occurred  at  sim-
lar  rates  in  the  total  perampanel  group  (4.0%,  n  =  41)  and
he  placebo  group  (3.5%,  n  =  15),  and  showed  no  dose-
elated  trends.  For  the  parameter  of  total  bilirubin,  1  (0.1%)
erampanel-treated  patient  had  a  value  >2×  ULN.  This
atient,  randomized  to  the  2  mg/day  perampanel  group,  was
 24-year-old  female  with  a  history  of  hepatitis  who  had
ilirubin  values  of  39  mol/L  at  baseline  and  34—48  mol/L
80
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Table  1  Hepatobiliary  laboratory  results:  shift  from  baseline  to  end  of  treatment.
Laboratory  test
(unit);  End-of-
treatment
category
Placebo  (N  =  442)  Perampanel  (N  =  1038)
Baseline  category
Low  n  (%) Normal  n  (%) High  n  (%)  Total  n  (%)  Missing  n  Low  n  (%)  Normal  n  (%)  High  n  (%)  Total  n  (%)  Missing  n
ALP  (IU/L)
Low,  n  (%) 13  (3.0)  9  (2.1)  0  22  (5.1)  0  28  (2.8)  19  (1.9)  0  47  (4.6)  0
Normal, n  (%)  3  (0.7)  357  (82.8)  15  (3.5)  375  (87.0)  0  11  (1.1)  829  (81.6)  24  (2.4)  864  (85.0)  0
High, n  (%)  0  9  (2.1)  25  (5.8)  34  (7.9)  0  0  23  (2.3)  82  (8.1)  105  (10.3)  0
Total, n  (%)  16  (3.7)  375  (87.0)  40  (9.3)  431  (100.0)  0  39  (3.8)  871  (85.7)  106  (10.4)  1016  (100.0)  0
Missing 1  9  1  11  0  0  21  1  22  0
ALT (IU/L)
Low,  n  (%)  0  0  0  0  0  0  1  (0.1)  0  1  (0.1)  0
Normal, n  (%)  0  392  (91.2)  17  (4.0)  409  (95.1)  0  5  (0.5)  947  (93.3)  30  (3.0)  982  (96.7)  0
High, n  (%)  0  11  (2.6)  10  (2.3)  21  (4.9)  0  0  17  (1.7)  15  (1.5)  32  (3.2)  0
Total, n  (%)  0  403  (93.7)  27  (6.3)  430  (100.0)  0  5  (0.5)  965  (95.1)  45  (4.4)  1015  (100.0)  0
Missing 0  12  0  12  0  0  23  0  23  0
AST (IU/L)
Low,  n  (%)  4  (0.9)  3  (0.7)  0  7  (1.6)  0  7  (0.7)  9  (0.9)  0  16  (1.6)  0
Normal, n  (%)  5  (1.2)  402  (93.5)  7  (1.6)  414  (96.3)  0  11  (1.1)  955  (94.3)  15  (1.5)  981  (96.8)  1
High, n  (%)  0  7  (1.6)  2  (0.5)  9  (2.1)  0  0  11  (1.1)  5  (0.5)  16  (1.6)  0
Total, n  (%)  9  (2.1)  412  (95.8)  9  (2.1)  430  (100.0)  0  18  (1.8)  975  (96.2)  20  (2.0)  1013  (100.0)  1
Missing 0  12  0  12  0  0  24  0  24  0
GGT (IU/L)
Low,  n  (%)  0  1  (0.2)  0  1  (0.2)  0  0  0  0  0  0
Normal, n  (%)  0  257  (59.6)  22  (5.1)  279  (64.7)  0  1  (0.1)  659  (64.9)  54  (5.3)  714  (70.3)  0
High, n  (%)  0  19  (4.4)  132  (30.6)  151  (35.0)  0  0  24  (2.4)  278  (27.4)  302  (29.7)  0
Total, n  (%)  0  277  (64.3)  154  (35.7)  431  (100.0)  0  1  (0.1)  683  (67.2)  332  (32.7)  1016  (100.0)  0
Missing 0  8  3  11  0  0  16  6  22  0
Total bilirubin  (mol/L)
Low,  n  (%)  2  (0.5)  14  (3.2)  0  16  (3.7)  0  6  (0.6)  34  (3.3)  0  40  (3.9)  0
Normal, n  (%)  12  (2.8)  403  (93.5)  0  415  (96.3)  0  31  (3.1)  940  (92.5)  2  (0.2)  973  (95.8)  0
High, n  (%)  0  0  0  0  0  0  2  (0.2)  1  (0.1)  3  (0.3)  0
Total, n  (%)  14  (3.2)  417  (96.8)  0  431  (100.0)  0  37  (3.6)  976  (96.1)  3  (0.3)  1016  (100.0)  0
Missing 0  11  0  11  0  1  21  0  22  0
ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; GGT = gamma-glutamyl transpeptidase. Subjects treated during the double-blind study. Dose
groups are based on the actual treatment groups. Percentages are based on the number of subjects with non-missing data at both baseline and post-baseline.
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Table  2  Treatment-emergent  markedly  abnormal  results  for  hepatobiliary  parameters.
Laboratory
test  (unit)
Placebo
(n  =  442)
Perampanel
2  mg/day
(n  =  180)
4  mg/day
(n  =  172)
8  mg/day
(n  =  431)
12  mg/day
(n  =  255)
Total
(n  =  1038)
ALP  (IU/L)
N  431  179  169  422  246  1016
Markedly abnormal
high,  n  (%)
0  0  0  0  0  0
ALT (IU/L)
N  430  179  168  422  246  1015
Markedly abnormal
high,  n  (%)
1  (0.2)  0  1  (0.6)  1  (0.2)  0  2  (0.2)
AST (IU/L)
N  430  179  168  421  246  1014
Markedly abnormal
high,  n  (%)
0  1  (0.6)  2  (1.2)  2  (0.5)  0  5  (0.5)
GGT (IU/L)
N  431  179  169  422  246  1016
Markedly abnormal
high,  n  (%)
12  (2.8)  4  (2.2)  3  (1.8)  13  (3.1)  7  (2.8)  27  (2.7)
Total bilirubin
(mol/L)
N  431  179  169  422  246  1016
Markedly abnormal 0  2  (1.1)  0  0  0  2  (0.2)
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ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST =
at  all  post-baseline  evaluations,  all  of  which  were  above  nor-
mal  range  (3—21  mol/L).  Her  values  for  ALP,  ALT,  and  AST
were  within,  or  slightly  below,  the  normal  ranges  at  each
evaluation.  This  patient  had  no  adverse  events  during  the
study.
No  patient  had  values  that  met  the  criteria  for  Hy’s  Law
(i.e.,  AST  or  ALT  >3×  ULN,  total  bilirubin  >2×  ULN,  and  ALP
<2×  ULN)  (Table  3  and  Fig.  3).  In  Fig.  3, the  Evaluation
of  Drug-Induced  Serious  Hepatotoxicity  (eDISH)  (Watkins
et  al.,  2011)  approach  shows  that  1  (0.2%)  patient  receiv-
ing  placebo  and  3  (0.3%)  patients  receiving  perampanel  met
the  criteria  for  Temple’s  Corollary  (ALT  >3×  ULN  but  not
satisfying  Hy’s  Law).  Further  analysis  of  these  4  subjects
showed  that  hepatobiliary  laboratory  test  values  did  not
increase  with  perampanel  treatment  during  the  course  of
the  study  and  the  reported  abnormalities  appear  to  be
isolated  ﬁndings  (Fig.  4).  These  subjects  completed  the
double-blind  study  and  continued  with  the  open-label  exten-
sion  study,  with  no  patient  meeting  Hy’s  Law  or  Temple’s
Corollary  criteria  during  the  extension.
TEAEs  related  to  hepatobiliary  parametersTEAEs  related  to  hepatobiliary  parameters  occurred  in  0.4%
(n  =  4)  of  total  perampanel-treated  patients  and  0%  (n  =  0)  of
placebo-treated  patients.  These  TEAEs  included  cholelithi-
asis,  which  occurred  in  perampanel  patients  receiving  4  mg
i
o
l
ttate aminotransferase; GGT = gamma-glutamyl transpeptidase.
0.6%,  n  =  1),  8  mg  (0.2%,  n  =  1),  and  12  mg  (0.4%,  n  =  1);  and
bnormal  hepatic  function,  which  occurred  in  1  perampanel
atient  treated  with  4  mg  (0.6%).  None  of  the  events  was
erious,  and  none  led  to  discontinuation  of  perampanel.
he  patient  with  abnormal  hepatic  function  was  one  of  the
atients  who  met  the  criteria  for  Temple’s  Corollary.
ubgroup  analysis  of  hepatobiliary  data  by  baseline
oncomitant AED
o  determine  whether  concomitant  AEDs  had  an  effect
n  any  hepatobiliary  parameters,  a  subgroup  analysis  was
erformed.  In  this  analysis,  concomitant  AEDs  included  car-
amazepine,  lamotrigine,  levetiracetam,  oxcarbazepine,
opiramate,  and  valproic  acid.  Patients  taking  carba-
azepine,  lamotrigine,  topiramate,  and  valproic  acid  were
ecorded  to  have  TEAEs  related  to  hepatobiliary  parameters
cholelithiasis  or  abnormal  hepatic  function).  However,  no
eaningful  differences  with  any  speciﬁc  AED  were  observed.
reatment-emergent  markedly  abnormal  laboratory  results
i.e.,  an  increase  in  NCI-CTC  grade  relative  to  baseline
nd  a  grade  ≥2)  for  hepatobiliary  parameters  by  concomi-
ant  AEDs  were  also  examined.  In  this  subanalysis,  the
ncidence  of  treatment-emergent  markedly  abnormal  lab-
ratory  results  for  AST,  ALT,  ALP,  and  total  bilirubin  was
ess  than  1%  for  the  concomitant  AEDs  in  the  placebo  and
otal  perampanel  groups.  Treatment-emergent  markedly
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Table  3  Subjects  with  laboratory  values  of  special  interest.
Laboratory  test
category,  n  (%)
Placebo
(n  =  442)
Perampanel
2  mg/day
(n  =  180)
4  mg/day
(n  =  172)
8  mg/day
(n  =  431)
12  mg/day
(n  =  255)
Total
(n  =  1038)
ALP
≤3×  ULN  431  (100.0)  179  (100.0)  169  (100.0)  421  (99.8)  246  (100.0)  1015  (99.9)
>3× and  ≤5×  ULN 0  0  0  1  (0.2)  0  1  (0.1)
>5× ULN 0  0  0  0  0  0
ALT
≤3× ULN  429  (99.8)  178  (99.4)  167  (99.4)  421  (99.8)  246  (100.0)  1012  (99.7)
>3× and  ≤5×  ULN  1  (0.2)  1  (0.6)  1  (0.6)  1  (0.2)  0  3  (0.3)
>5× ULN  0  0  0  0  0  0
AST
≤3× ULN  429  (99.8)  178  (99.4)  166  (98.8)  419  (99.5)  246  (100.0)  1009  (99.5)
>3× and  ≤5×  ULN  1  (0.2)  1  (0.6)  2  (1.2)  2  (0.5)  0  5  (0.5)
>5× ULN  0  0  0  0  0  0
GGT
≤3× ULN  407  (94.4)  167  (93.3)  160  (94.7)  397  (94.1)  233  (94.7)  957  (94.2)
>3× and  ≤5×  ULN  15  (3.5)  7  (3.9)  7  (4.1)  17  (4.0)  10  (4.1)  41  (4.0)
>5× ULN  9  (2.1)  5  (2.8)  2  (1.2)  8  (1.9)  3  (1.2)  18  (1.8)
Total bilirubin
≤2×  ULN  431  (100.0)  178  (99.4)  169  (100.0)  422  (100.0)  246  (100.0)  1015  (99.9)
>2× ULN  0  1  (0.6)  0  0  0  1  (0.1)
Hy’s Lawa
Yes  0  0  0  0  0  0
No 430  (100.0)  179  (100.0)  168  (100.0)  421  (100.0)  246  (100.0)  1014  (100.0)
ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; GGT = gamma-glutamyl transpeptidase;
PER = perampanel; ULN = upper limit of normal.
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ia Hy’s Law is satisﬁed when AST or ALT >3× ULN, total bilirubin 
bnormal  laboratory  values  for  ALT  and  total  bilirubin  were
eported  in  perampanel-treated  patients  taking  concomi-
ant  carbamazepine  (n  =  2,  0.6%;  n  =  1,  0.3%;  respectively)
nd  valproic  acid  (n  =  2,  0.6%;  n  =  2,  0.6%;  respectively);  for
ST  in  patients  taking  lamotrigine  (n  =  2,  0.6%),  levetirac-
tam  (n  =  2,  0.7%),  oxcarbazepine  (n  =  1,  0.6%),  topiramate
n  =  1,  0.5%),  and  valproic  acid  (n  =  3,  0.9%);  and  in  no  patient
or  ALP.  For  GGT,  the  incidence  of  treatment-emergent
arkedly  abnormal  laboratory  values  was  similar  between
atients  treated  with  perampanel  (range:  1.5—3.2%)  and
hose  treated  with  placebo  (range:  1.6—3.6%)  for  all
oncomitant  AEDs.  Taken  together,  treatment-emergent
arkedly  abnormal  laboratory  values  showed  no  meaningful
ifferences  with  any  speciﬁc  AED.
iscussion
he  liver  plays  a  major  role  in  the  metabolism  of  a  major-
ty  of  drugs,  including  AEDs  (Ahmed  and  Siddiqi,  2006;
ussein  et  al.,  2013;  Lee,  1995).  Hepatotoxicity  is  rare,  and
an  be  a  result  of  metabolites  or  toxic  by-products  that
an  disrupt  the  integrity  of  the  hepatocyte  structure  and
b
(
R
tULN, and ALP <2× ULN at the same visit.
unction  (Ahmed  and  Siddiqi,  2006;  Lee,  1995).  Because  the
iver  is  the  primary  elimination  route  for  many  AEDs  and
dministration  of  some  of  these  AEDs  has  resulted  in  ele-
ated  liver  enzymes  (markers  of  hepatocellular  injury),  it  is
mportant  to  assess  and  understand  the  potential  for  liver
oxicity  with  new  AEDs  (Ahmed  and  Siddiqi,  2006;  Lee,  1995;
arner  et  al.,  1998).  Although  the  mild  elevations  of  liver
nzymes  can  be  transitory,  monitoring  of  hepatic  function
s  recommended  for  some  AEDs  (Ahmed  and  Siddiqi,  2006;
arner  et  al.,  1998).  When  liver  enzyme  levels  increase  to
3×  ULN,  there  is  a  potential  for  liver  disease  and  clinicians
ay  consider  dose  reduction  of  the  AED  or  discontinuation
nd  switching  to  a  different  AED  (Ahmed  and  Siddiqi,  2006;
arner  et  al.,  1998).
Here  we  demonstrate  that  the  ﬁrst-in-class  AED  peram-
anel  has  no  clinically  important  effects  on  liver  function
ests,  indicating  low  potential  for  liver  toxicity.  Per-
mpanel,  an  adjunctive  treatment  for  partial  seizures,
s  extensively  metabolized  via  primary  oxidation  (mainly
y  CYP3A4  and  CYP3A5)  and  sequential  glucuronidation
FYCOMPA  Prescribing  Information,  2014;  Rektor,  2013;
ogawski  and  Hanada,  2013).  Some  of  the  metabolites  iden-
iﬁed  for  perampanel  appear  likely  to  be  formed  via  reactive
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aFig.  3  Distribution  of  peak  values.  ALT  =  alanine  amino
intermediates  (Rheims  and  Ryvlin,  2013).  Idiosyncratic  tox-
icities,  including  hepatotoxicity,  have  been  associated  with
the  mechanism  in  which  reactive  intermediates  covalently
bind  to  proteins,  especially  if  reduced  glutathione  (GSH)  lev-
els  have  become  depleted  (Ballet,  2010;  Begriche  et  al.,
2011;  Lammert  et  al.,  2010).  Covalent  binding  has  been
observed  in  preclinical  studies  of  perampanel,  at  exposures
much  higher  than  clinical  exposures.  Importantly,  there  is
evidence  that  idiosyncratic  toxicities  are  rare  when  the
clinical  daily  dose  of  drug  is  given  at  daily  doses  ≤10  mg
(Ballet,  2010;  Evans  et  al.,  2004;  Nakayama  et  al.,  2009;
Uetrecht,  2001).  The  daily  clinical  dose  for  perampanel
is  4—12  mg/day,  which  compares  favorably  relative  to  the
much  higher  doses  of  other  AEDs  known  to  cause  idiosyn-
cratic  toxicities  (Nakayama  et  al.,  2009),  providing  further
support  for  perampanel’s  low  potential  of  hepatotoxicity.
Laboratory  tests  measuring  liver  enzyme  levels  revealed
that  the  mean  values  of  ALP,  ALT,  AST,  GGT,  and  total
bilirubin  were  within  normal  ranges  at  baseline  and  at
end  of  treatment  in  patients  taking  all  therapeutic  doses
of  perampanel  (4—12  mg).  Markedly  abnormal  results  for
liver  enzymes  were  very  infrequent  in  perampanel-treated
patients  and  no  dose-related  trends  in  abnormal  results
were  observed,  suggesting  normal  liver  function.  No  seri-
ous  adverse  events  related  to  the  liver  were  observed,  and
no  perampanel-treated  patients  discontinued  due  to  TEAEs
related  to  hepatobiliary  parameters.
Although  some  patients  had  liver  enzymes  >3×  ULN,  the
percentages  were  low  and  were  similar  for  perampanel-
and  placebo-treated  patients.  There  were  no  reports  of
patients  from  the  phase  III  perampanel  clinical  stud-
ies  meeting  the  criteria  for  Hy’s  Law.  A  predictor  of  a
drug’s  potential  to  induce  liver  toxicity  is  the  occurrence
of  hepatocellular  injury  (indicated  by  aminotransferase
h
asferase;  PER  =  perampanel;  ULN  =  upper  limit  of  normal.
levation)  accompanied  by  increased  serum  total  bilirubin,
ot  explained  by  any  other  cause  and  without  evidence  of
holestasis,  compared  to  placebo/control  (US  Food  and  Drug
dministration  Guidance  for  Industry,  2009).  The  evaluation
f  Drug-Induced  Serious  Hepatotoxicity  (eDISH)  is  a  tool  that
raphically  displays  peak  serum  ALT  and  total  bilirubin  lev-
ls  obtained  from  laboratory  data  for  each  subject  (Watkins
t  al.,  2011).  Here  we  present  a  similar  graphic  (Fig.  3)  for
he  patients  in  the  3  phase  III  perampanel  studies.  Temple’s
orollary  (ALT  >3×  ULN  but  not  satisfying  Hy’s  Law)  (Watkins
t  al.,  2011) was  reported  in  both  perampanel  (n  =  3,  0.3%)
nd  placebo  (n  =  1,  0.2%)  patients.  Over  the  course  of  per-
mpanel  treatment,  hepatobiliary  laboratory  test  values  did
ot  increase,  suggesting  that  in  these  patients  the  reported
bnormalities  appear  to  be  isolated  ﬁndings.  These  results
urther  highlight  the  low  potential  for  liver  toxicity  with
erampanel.
Routine  monitoring  of  liver  enzymes  has  not  been
ndicated  for  perampanel,  and  for  patients  who  have  dis-
ontinued  other  AEDs  due  to  elevations  in  liver  enzymes,
 switch  to  an  alternative  AED  (Ahmed  and  Siddiqi,  2006),
uch  as  perampanel,  may  be  considered.  However,  the  con-
omitant  AEDs  taken  when  patients  are  on  polytherapy  to
ontrol  seizures  need  to  be  evaluated  to  ensure  that  they
o  not  have  the  potential  to  cause  liver  toxicity.  Some  AEDs
ave  led  to  the  elevation  of  ALP,  ALT,  AST,  and  GGT  (Ahmed
nd  Siddiqi,  2006).  We  have  demonstrated  through  an  anal-
sis  of  hepatobiliary  parameters  stratiﬁed  by  AED  taken
ith  perampanel  that  concomitant  use  with  carbamazepine,
amotrigine,  levetiracetam,  oxcarbazepine,  topiramate,
nd  valproic  acid  did  not  yield  any  meaningful  changes  in
epatobiliary  parameters.
Hepatic  impairment  can  affect  the  pharmacokinetics  of
 drug  (Verbeeck,  2008).  Based  on  PK  data  in  patients  with
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Fig.  4  Hepatobiliary  laboratory  test  values  in  patients  meeting  Temple’s  Corollary  criteria. *  An  unscheduled  visit  occurred  at  day
7 post  baseline.  ALP  =  alkaline  phosphatase;  ALT  =  alanine  aminotransferase;  AST  =  aspartate  aminotransferase;  BILI  =  total  bilirubin;
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DGT =  gamma-glutamyl  transpeptidase;  PBO  =  placebo;  PER  =  pe
epatic  impairment,  dosage  adjustments  are  recommended
or  perampanel  in  patients  with  mild  to  moderate  hepatic
mpairment.
(FYCOMPA  Prescribing  Information,  2014),  which  is  con-
istent  with  recommendations  for  drugs  metabolized  by  the
iver  (Verbeeck,  2008).  The  following  maximum  daily  doses
re  recommended  due  to  the  higher  exposure  and  the  longer
alf-life  of  perampanel  in  patients  with  mild  and  moderate
epatic  impairment:  6  mg  once  daily  at  bedtime  for  patients
ith  mild  hepatic  impairment  and  4  mg  once  daily  at  bed-
ime  for  patients  with  moderate  hepatic  impairment,  with
osage  increases  no  more  frequently  than  every  2  weeks
FYCOMPA  Prescribing  Information,  2014).onclusion
erampanel  did  not  demonstrate  clinically  important  effects
n  liver  function  tests  at  any  doses  (2—12  mg/day).
T
ianel;  ULN  =  upper  limit  of  normal.
epatobiliary  laboratory  data  and  related  TEAEs  were  not
otably  different  between  the  perampanel  and  placebo
reatment  groups  from  the  3  Phase  III  clinical  studies,  and
o  dose-related  trends  were  observed.  TEAEs  related  to
epatobiliary  parameters  were  not  considered  serious  and
id  not  lead  to  perampanel  discontinuation.  Although  per-
mpanel  is  extensively  metabolized  via  primary  oxidation
mainly  by  CYP3A4  and  CYP3A5)  and  sequential  glucuronida-
ion,  (FYCOMPA  Prescribing  Information,  2014;  Rektor,  2013;
ogawski  and  Hanada,  2013),  the  data  based  on  clinical  lab-
ratory  tests  suggest  that  patients  treated  with  perampanel
ave  a  low  potential  for  liver  toxicity.
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